Search

everythinglearnresearchcommunity

for

Search:↓

Azathioprine is the most continued treatment for chronic alopecia areata over a year, often with added low-dose prednisolone.

Itraconazole effectively treats scalp fungus, with continuous use more effective than pulse therapy.

Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.

The cream with turmeric and ginger extracts can potentially reduce underarm hair growth effectively.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

Topical thiols may prevent hair loss caused by certain chemotherapy drugs.

AGA might indicate higher risk for severe COVID-19.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

Combining pentoxifylline with corticosteroids improves alopecia areata treatment.

Midazolam reduces PTSD-like behavior in rats by acting on specific brain receptors.

Smaller, diluted corticosteroid injections reduce the risk of vision loss.

SCD-153 shows promise as an effective topical treatment for alopecia areata.

Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.

The NUDT15 gene variant causes severe side effects from azathioprine in some Indian patients.

Researchers developed a simple, low-cost method to accurately measure Aminexil in hair tonic.

Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.

Intralesional steroid injections are safe and effective for treating severe alopecia areata.

Antihistamines may help with hair regrowth in alopecia areata, but dupilumab's effects are mixed.

A reliable method was developed to measure aristolochic acid-I in rat blood.

Squaric acid dibutylester can cause severe skin reactions in people with allergies.

Delonix polymeric nanoparticles with isotretinoin effectively treat acne by targeting hair follicles and reducing skin irritation.

Apremilast did not work for treating severe alopecia areata.

Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

New itaconate prodrugs improve its absorption and effectiveness for treating inflammation.

Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.